Limits...
Research and development in drug innovation: reflections from the 2013 bioeconomy conference in China, lessons learned and future perspectives.

Liu C, Constantinides PP, Li Y - Acta Pharm Sin B (2014)

Bottom Line: We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation.More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed.Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

View Article: PubMed Central - PubMed

Affiliation: Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China.

ABSTRACT
The enormous progress biotechnology, bioinformatics and nanotechnology made in recent years provides opportunities and scientific framework for development of biomedicine and constitutes a paradigm shift in pharmaceutical R&D and drug innovation. By analyzing the data and related information at R&D level over the past decades, developmental tendency and R&D patterns were summarized. We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation. Additionally, small/medium size companies will continue to play a key role in the development of small molecule drugs and biologics in a multi-channel integrated process. More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed. To face new challenges, developmental strategies were proposed, in terms of molecular targeted medicine, generic drugs, new drug delivery system and protein-based drugs. Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

No MeSH data available.


Related in: MedlinePlus

The mean annual new molecular entitie (NME) output of large and small companies. a, actual versus expected shares of NMEs for large and small pharmaceutical companies; b, mean annual NME output for small companies.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4590300&req=5

f0015: The mean annual new molecular entitie (NME) output of large and small companies. a, actual versus expected shares of NMEs for large and small pharmaceutical companies; b, mean annual NME output for small companies.

Mentions: This analysis shows that the rate of production of new drugs by these companies has been constant since they began producing drugs with some variability in rates between companies. It is a fact that the cost per new molecular entity has been steadily increasing over the last decades. A puzzling trend in recent years, however, has been the gradual erosion in the share of innovation that is captured by NMEs discovered by large pharmaceutical companies. Since the early 1980s, their share of NMEs has declined from 75%, a level that had been constant since 1950, to 35% (Fig. 3a). At the same time, the share of NMEs that is attributable to small biotechnology and pharmaceutical companies has almost tripled, from 23% to nearly 70%. Since 2004, small companies have consistently matched or outperformed their larger competitors. The expected share of NMEs generally follows these trends until 2004, when they stabilized at about 50% each22.


Research and development in drug innovation: reflections from the 2013 bioeconomy conference in China, lessons learned and future perspectives.

Liu C, Constantinides PP, Li Y - Acta Pharm Sin B (2014)

The mean annual new molecular entitie (NME) output of large and small companies. a, actual versus expected shares of NMEs for large and small pharmaceutical companies; b, mean annual NME output for small companies.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4590300&req=5

f0015: The mean annual new molecular entitie (NME) output of large and small companies. a, actual versus expected shares of NMEs for large and small pharmaceutical companies; b, mean annual NME output for small companies.
Mentions: This analysis shows that the rate of production of new drugs by these companies has been constant since they began producing drugs with some variability in rates between companies. It is a fact that the cost per new molecular entity has been steadily increasing over the last decades. A puzzling trend in recent years, however, has been the gradual erosion in the share of innovation that is captured by NMEs discovered by large pharmaceutical companies. Since the early 1980s, their share of NMEs has declined from 75%, a level that had been constant since 1950, to 35% (Fig. 3a). At the same time, the share of NMEs that is attributable to small biotechnology and pharmaceutical companies has almost tripled, from 23% to nearly 70%. Since 2004, small companies have consistently matched or outperformed their larger competitors. The expected share of NMEs generally follows these trends until 2004, when they stabilized at about 50% each22.

Bottom Line: We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation.More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed.Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

View Article: PubMed Central - PubMed

Affiliation: Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China.

ABSTRACT
The enormous progress biotechnology, bioinformatics and nanotechnology made in recent years provides opportunities and scientific framework for development of biomedicine and constitutes a paradigm shift in pharmaceutical R&D and drug innovation. By analyzing the data and related information at R&D level over the past decades, developmental tendency and R&D patterns were summarized. We found that a growing number of biologics in the pipeline of pharma companies with successful products already in the market though, small molecular entities have primarily dominated drug innovation. Additionally, small/medium size companies will continue to play a key role in the development of small molecule drugs and biologics in a multi-channel integrated process. More importantly, modern and effective R&D strategies in biomedicine development to predict and evaluate efficacy and/or safety of 21st century therapeutics are urgently needed. To face new challenges, developmental strategies were proposed, in terms of molecular targeted medicine, generic drugs, new drug delivery system and protein-based drugs. Under the current circumstances, interdisciplinary cooperation mode and policy related to drug innovation in China were deeply discussed as well.

No MeSH data available.


Related in: MedlinePlus